Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Comparison of Biphasic Insulin Aspart 70/30 With Anti-Diabetic Drugs in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 230
- Registration Number
- NCT00097279
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 299
- Registration Number
- NCT00097071
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Milwaukee, Wisconsin, United States
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00097084
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Ängelholm, Sweden
NovoLog Observation Trial in Subjects With Type 1 and Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- First Posted Date
- 2004-11-05
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 513
- Registration Number
- NCT00095446
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States
Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 1Diabetes
- First Posted Date
- 2004-11-01
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 447
- Registration Number
- NCT00095082
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Wirral, Merseyside, United Kingdom
Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- First Posted Date
- 2003-10-24
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 378
- Registration Number
- NCT00071448
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Madison, Wisconsin, United States
Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes
Phase 3
Completed
- Conditions
- Gestational DiabetesDiabetes
- First Posted Date
- 2003-07-18
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 27
- Registration Number
- NCT00065130
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Santa Barbara, California, United States
Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency
Phase 1
Completed
- Conditions
- Congenital Bleeding DisorderCongenital FXIII Deficiency
- Interventions
- First Posted Date
- 2003-03-20
- Last Posted Date
- 2017-01-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 11
- Registration Number
- NCT00056589
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath